Literature DB >> 2662703

The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease).

J T Lie1.   

Abstract

Thromboangiitis obliterans (TAO; or Buerger's disease) is a nonarteriosclerotic, segmental, occlusive inflammatory disease of medium-sized and small arteries and veins of unknown cause, occurring predominantly in young male habitual tobacco users. Less than 2% of the patients with TAO are women or elderly persons. TAO is a treatable disease when diagnosed early and if strict abstinence from tobacco is observed. Otherwise progression and exacerbation of limb ischemia may lead to multiple and repeated amputations, and rarely visceral or cerebral ischemia. Over a 40-year period, 1947 to 1986, the prevalence rate of the diagnosis of TAO has declined steadily from 104/100,000 in 1947 to 13/100,000 in 1986 (an 8-fold decrease) where clinical and pathologic criteria for the diagnosis of TAO have remained unchanged. A similar pattern of decline was observed in two other major medical centers. Twelve women and 97 men with TAO were identified in the 5-year period 1981-1985. The 11% (12 of 109) incidence of female TAO was 10-fold that was previously reported. All 12 women were heavy smokers; 8 (67%) had thrombophlebitis and 6 (50%) had upper limb ischemia. Nine (75%) of 12 women required amputations; delay in diagnosis contributed to additional amputations in 2 patients. The increased prevalence of TAO in women may be attributed to the smoking habit in young women overall, which has increased significantly rather than decreased (as in males) since 1965.

Entities:  

Mesh:

Year:  1989        PMID: 2662703     DOI: 10.1111/j.1440-1827.1989.tb01494.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  11 in total

1.  Distribution of arterial involvement in thromboangiitis obliterans (Buerger's disease): results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan.

Authors:  S Sasaki; M Sakuma; T Kunihara; K Yasuda
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Thromboangiitis Obliterans (Buerger's Disease).

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

3.  Decrease in the incidence of Buerger's disease recurrence in northern Thailand.

Authors:  Kamphol Laohapensang; Kittipan Rerkasem; Vinaisak Kattipattanapong
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

4.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

5.  Possible involvement of Notch signaling in the pathogenesis of Buerger's disease.

Authors:  Hiroaki Tamai; Masayoshi Kobayashi; Kyousuke Takeshita; Akio Kodama; Hiroshi Banno; Hiroshi Narita; Kiyohito Yamamoto; Kimihiro Komori
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

6.  The Wound Healing Effects of Iloprost in Patients with Buerger's Disease: Claudication and Prevention of Major Amputations.

Authors:  A Afsharfard; M Mozaffar; F Malekpour; A Beigiboroojeni; M Rezaee
Journal:  Iran Red Crescent Med J       Date:  2011-06-01       Impact factor: 0.611

Review 7.  Thromboangiitis obliterans (Buerger's disease).

Authors:  Perttu E T Arkkila
Journal:  Orphanet J Rare Dis       Date:  2006-04-27       Impact factor: 4.123

Review 8.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12

9.  Thromboangiitis Obliterans: 110 Years Old and Little Progress Made.

Authors:  Jeffrey W Olin
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

10.  The Incidence and Prevalence of Thromboangiitis Obliterans in Taiwan: A Nationwide, Population-based Analysis of Data Collected from 2002 to 2011.

Authors:  Jie-Fu Zheng; Yi-Ming Chen; Der-Yuan Chen; Ching-Heng Lin; Hsin-Hua Chen
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.